Pfizer
NEWS
Alexandria Real Estate Equities, an urban office real estate investment company specializing in the life sciences, is expanding its Alexandria LaunchLabs into the East Cambridge, Massachusetts area.
Cellectis has found some sure financial footing that will support its efforts through the remainder of the year. The company secured $163.7 million in an initial public offering to develop CART-T products.
An Independent Monitoring Committee recommended that Pfizer halt the Phase III ATLAS trial of Inlyta (axitinib) because it wasn’t proving effective.
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
Pfizer has signed a 20-year lease for its new company global headquarters. It will be, as reported earlier, at The Spiral, an office tower being built by Tishman Speyer at 66 Hudson Boulevard at Hudson Yards of Manhattan.
Pfizer joined the TriNetX global health research network, which will allow it to access clinical data from the network’s healthcare organizations.
Constellation Pharmaceuticals closed on a financing round worth $100 million. The company plans to use the funds to advance several clinical trials.
It’s no secret that drugmakers have struggled to develop a therapeutic to treat or halt the onset of Alzheimer’s disease. Multiple drugs have failed in late-stage trials and some companies, such as Pfizer, have largely given up on the space.
Arvinas closed a $55 million Series C financing round. The funds will be used to advance Arvinas’ two lead cancer programs into the clinic.
JOBS
IN THE PRESS